Nonhuman primate antigenic cartography of SARS-CoV-2

/in

Rössler A, Netzl A, Lasrado N, Chaudhari J, Mühlemann B, Wilks SH, Kimpel J, Smith DJ, Barouch DH. Nonhuman primate antigenic cartography of SARS-CoV-2. Cell Rep. 2025 Jan 28;44(1):115140. doi: 10.1016/j.celrep.2024.115140. Epub 2025 Jan 3. PMID: 39754717; PMCID: PMC11781863.

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

/in ,

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. Lancet HIV. 2025 Jan;12(1):e13-e25. doi: 10.1016/S2352-3018(24)00247-9. Epub 2024 Dec 10. PMID: 39667379; PMCID: PMC11795396.

Identification of a novel neutralization epitope in rhesus AAVs

/in

Dagotto, G., Fisher, J. L., Li, D., Li, Z., Jenni, S., Li, Z., Tartaglia, L. J., Abbink, P., & Barouch, D. H. (2024). Identification of a novel neutralization epitope in rhesus AAVs. Molecular therapy. Methods & clinical development, 32(4), 101350. https://doi.org/10.1016/j.omtm.2024.101350

Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial

/in

Gray, G. E., Mngadi, K., Lavreys, L., Nijs, S., Gilbert, P. B., Hural, J., Hyrien, O., Juraska, M., Luedtke, A., Mann, P., McElrath, M. J., Odhiambo, J. A., Stieh, D. J., van Duijn, J., Takalani, A. N., Willems, W., Tapley, A., Tomaras, G. D., Van Hoof, J., Schuitemaker, H., … Imbokodo/HVTN 705/HPX2008 Study Group (2024). Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet. Infectious diseases, 24(11), 1201–1212. https://doi.org/10.1016/S1473-3099(24)00358-X

Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques

/in

Nkolola JP, Hope D, Guan R, Colarusso A, Aid M, Weiss D, Misamore J, Andersen H, Lewis MG, Williamson L, Carnahan RH, Crowe JE, Barouch DH.2024.Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques. J Virol98:e01429-24.https://doi.org/10.1128/jvi.01429-24

Natural Killer Cell Phenotypes and Clinical Outcomes in Pediatric Kidney Transplantation

/in

Kahan, R. H., Abraham, N., Lee, H. J., Ettenger, R. B., Grimm, P. C., Reed, E. F., Reeves, R. K., Sarwal, M. M., Stempora, L. L., Warshaw, B. L., Kirk, A. D., Martinez, O. M., & Chambers, E. T. (2024). Natural Killer Cell Phenotypes and Clinical Outcomes in Pediatric Kidney Transplantation. Pediatric transplantation, 28(8), e14877. https://doi.org/10.1111/petr.14877

Severe Acute Respiratory Syndrome Coronavirus 2 Household Transmission During the Omicron Era in Massachusetts: A Prospective, Case-Ascertained Study Using Genomic Epidemiology

/in ,

Banga, J., Brock-Fisher, T., Petros, B. A., Dai, E. Y., Leonelli, A. T., Dobbins, S. T., Messer, K. S., Nathanson, A. B., Capone, A., Littlehale, N., Appiah-Danquah, V., Dim, S., Moreno, G. K., Crowther, M., DeRuff, K. C., MacInnis, B. L., Springer, M., Sabeti, P. C., & Stephenson, K. E. (2024). Severe Acute Respiratory Syndrome Coronavirus 2 Household Transmission During the Omicron Era in Massachusetts: A Prospective, Case-Ascertained Study Using Genomic Epidemiology. Open forum infectious diseases, 11(11), ofae591. https://doi.org/10.1093/ofid/ofae591

SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity

/in

Lasrado, N., Rowe, M., McMahan, K., Hachmann, N. P., Miller, J., Jacob-Dolan, C., Liu, J., Verrette, B., Gotthardt, K. A., Ty, D. M., Pereira, J., Mazurek, C. R., Hoyt, A., Collier, A. Y., & Barouch, D. H. (2024). SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity. Science translational medicine, 16(770), eadp8920. https://doi.org/10.1126/scitranslmed.adp8920

Decline of Mpox Antibody Responses After Modified Vaccinia Ankara–Bavarian Nordic Vaccination

/in ,

Collier, A. Y., McMahan, K., Jacob-Dolan, C., Liu, J., Borducchi, E. N., Moss, B., & Barouch, D. H. (2024). Decline of Mpox Antibody Responses After Modified Vaccinia Ankara-Bavarian Nordic Vaccination. JAMA, 332(19), 1669–1672. https://doi.org/10.1001/jama.2024.20951

Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study

/in

Kenny, A., van Duijn, J., Dintwe, O., Heptinstall, J., Burnham, R., Sawant, S., Zhang, L., Mielke, D., Khuzwayo, S., Omar, F. L., Stanfield-Oakley, S., Keyes, T., Dunn, B., Goodman, D., Fong, Y., Benkeser, D., Zou, R., Hural, J., Hyrien, O., Juraska, M., … Imbokodo Study and Correlates Group (2024). Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study. EBioMedicine, 108, 105320. https://doi.org/10.1016/j.ebiom.2024.105320